---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-034113"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:10:42.480543+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acasti Pharma regains Nasdaq minimum bid price compliance after reverse split

## Summary
- Received Nasdaq notice on July 24, 2023 confirming compliance with Listing Rule 5550(a)(2).
- Compliance achieved through a 1-for-6 reverse share split effective July 10, 2023.
- Company continues trading on Nasdaq Capital Market under symbol ACST.

## SEC filing metadata
- accession: 0000950170-23-034113
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000095017023034113/0000950170-23-034113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000095017023034113/acst-20230724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-034113
- JSON: https://secwatch.observer/filing/0000950170-23-034113.json
- Plain text: https://secwatch.observer/filing/0000950170-23-034113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.